...Continued

U.S. Gold Corp. to Participate at 2023 Mines and Money @ Resourcing Tomorrow Conference in London

Retrieved on: 
Wednesday, November 15, 2023
Business Design Centre, Permit, USAU, ...Continued, Gold, Rio Tinto (corporation), Mine, Industrial, Mining, Conference, Barrick Gold, Business, U.S. Gold

CHEYENNE, Wyo., Nov. 15, 2023 /PRNewswire/ -- U.S. Gold Corp. (Nasdaq: USAU) ("U.S. Gold" or the "Company") is pleased to announce that it will be presenting and exhibiting at the Mines and Money @ Resourcing Tomorrow conference (the "Conference"), to be held in London at the end of November.

Key Points: 
  • CHEYENNE, Wyo., Nov. 15, 2023 /PRNewswire/ -- U.S. Gold Corp. (Nasdaq: USAU) ("U.S. Gold" or the "Company") is pleased to announce that it will be presenting and exhibiting at the Mines and Money @ Resourcing Tomorrow conference (the "Conference"), to be held in London at the end of November.
  • The Conference will be held in-person at the Business Design Centre in London, UK from November 28-30, 2023.
  • Many of the world's largest mining companies will be attending and presenting, including Barrick Gold Corporation, BHP Group Limited and Rio Tinto Group.
  • The Company expects to have a full schedule of one-on-one meetings at the conference in addition to George Bee's presentation.

Latham Group, Inc. Reports Third Quarter Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, Insurance, Fiscal, Public expenditure, SG, EBITDA, Environment, Capital expenditure, ...Continued, Capital, Bookkeeping, Reinsurance, Renewable energy, Pharmaceutical industry

LATHAM, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Latham Group, Inc. (“Latham” or “the Company”) (Nasdaq: SWIM), the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand, today announced financial results for the third quarter and first nine months of its fiscal year 2023 ended September 30, 2023.

Key Points: 
  • Gross profit for the third quarter of fiscal 2023 was $48.1 million, down $10.7 million or 18.2%, from $58.9 million in the prior year’s third quarter.
  • Adjusted EBITDA for the third quarter of fiscal 2023 was $36.1 million, down $6.2 million or 14.6%, from $42.3 million in the prior year’s third quarter.
  • Capital expenditures totaled $4.9 million in the third quarter of fiscal 2023 compared to $12.3 million in the third quarter of fiscal 2022.
  • Latham has updated its net sales, adjusted EBITDA and capital expenditures guidance for the full year fiscal 2023.

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

Retrieved on: 
Friday, November 3, 2023
MMC, MD, Conditional sentence, Doctor of Philosophy, Ruxolitinib, Research, Morphic, Bone marrow, ...Continued, AbbVie, Patient, Pharmaceutical industry, UC

WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023.

Key Points: 
  • -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027-
    WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023.
  • “Morphic presented a comprehensive set of positive results from the 12-week induction phase of the EMERALD-1 study of MORF-057 in UC, showing consistent efficacy across-the-board for patients, while demonstrating no safety signals.
  • These results are particularly impressive, given that enrollment was skewed towards the severe end of the spectrum of moderately-to-severely active UC.
  • The increase was due to increased non-cash stock-based compensation expenses and higher payroll costs
    As of September 30, 2023, Morphic had cash, cash equivalents and marketable securities of $725.1 million, compared to $731.4 million as of June 30, 2023.

FNCB Bancorp, Inc. Announces Third Quarter 2023 Results

Retrieved on: 
Monday, October 30, 2023
Bank, Tier 1, ALCO, Sale, Acquisition, ...Continued, Culture, Converse (logic), Mergers and acquisitions, Champissage, Total, People's Bank, ACL, ASU, FOMC, FTE, FHLB, Annual report, Cryptocurrency, Video game

FNCB's tax-equivalent net interest margin contracted 58 basis points to 2.85% for the third quarter of 2023 from 3.43% for the same quarter of 2022.

Key Points: 
  • FNCB's tax-equivalent net interest margin contracted 58 basis points to 2.85% for the third quarter of 2023 from 3.43% for the same quarter of 2022.
  • The tax-equivalent net interest margin increased 10 basis points from 2.75% for the second quarter of 2023.
  • FNCB's average deposit costs increased 187 basis points to 2.23% for the third quarter of 2023 compared to 0.36% for the same quarter of 2022.
  • Moreover, the average cost of borrowed funds increased 238 basis points to 4.94% for the third quarter of 2023 from 2.56% for the same quarter of 2022.

Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024

Retrieved on: 
Saturday, October 28, 2023
Yoy, ICH, ESG, US, McNeil Consumer Healthcare, US FDA, Sustainability reporting, CDMO, Social, H1, Growth, Stock, The Littles, GHG, ...Continued, IA, Social Security Government Pension Offset, Renewable energy, Pharmaceutical industry, EBITDA, Environment, Grangemouth

Our CDMO business returned to mid-teen growth with continued order inflows, especially for differentiated offerings and innovation related work.

Key Points: 
  • Our CDMO business returned to mid-teen growth with continued order inflows, especially for differentiated offerings and innovation related work.
  • Our capacity expansion for Inhalation Anesthesia products is progressing well as we look to capitalize on the healthy demand in the global market.
  • Historically our H2 has been better than H1, both in terms of revenue and profitability.
  • We now have presence across more than 20 e-commerce platforms including our own direct-tocustomer website -Wellify.in

Drug detection dogs often get it wrong, and it's a policing practice that needs to stop

Retrieved on: 
Thursday, October 26, 2023
Man, Policy, Drug, Prohibition, Health, Ecstasy, Government, Research, Law enforcement, Death, Violence, NSW, Risk, EDRS, ...Continued, Police, Dog, IDRS, Nightclub, Risk management, Vaccine, Pharmaceutical industry

Drug detection dogs are a street-level policing strategy that has now been used in Australia for more than 25 years.

Key Points: 
  • Drug detection dogs are a street-level policing strategy that has now been used in Australia for more than 25 years.
  • Since that time, increasing evidence has challenged the effectiveness and legality of this policing strategy.
  • In fact, policing and law enforcement, including police drug dogs operations, accounts for nearly two-thirds of Australian government spending on illegal drugs.
  • Our recent research shows police drug dogs are both an ineffective and inequitable strategy, which may carry health, social, and legal risks.

An ineffective strategy

  • This included how individuals responded to the presence of dogs and how they prepared for anticipated encounters.
  • We found encounters with drug dogs at festivals were common.
  • In fact, the vast majority (94%) of those who reported such encounters said they had anticipated the presence of drug dogs.

An inequitable approach

  • We found both samples of people commonly reported encounters with drug dogs in locations beyond festivals.
  • Existing evidence indicates that prior interactions with police increase the likelihood of a stop and/or search encounter with police drug dogs.
  • Our findings, combined with the existing research, suggest police drug dogs are ineffective and inequitable.
  • They should be removed from all community settings, including music festivals, public transportation hubs, and other public places.
  • She is President of the International Society for the Study of Drug Policy.
  • She previously received untied educational grants from Seqirus for post-marketing surveillance of opioid medications in Australia.

Integra LifeSciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, October 25, 2023
Food, CSF, Amniotic fluid, ICP, Clarity, SIA, GAAP, Acquisition, Regulation of tobacco by the U.S. Food and Drug Administration, Maintenance (technical), Electrosurgery, TWC, Integra, Growth, Advanced Energy, EPS, CUSA, ...Continued, Total, Codman, Integra LifeSciences, Security (finance), Medical device, Pharmaceutical industry, Music, Video game, Bank, Instrument

PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.

Key Points: 
  • PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.
  • The Company reported GAAP gross margin of 57.1%, compared to 61.5% in the third quarter of 2022.
  • Adjusted EBITDA for the third quarter of 2023 was $88.1 million, or 23.0% of revenue, compared to $105.3 million, or 27.3% of revenue, in the prior year.
  • ET on Wednesday, October 25, 2023, to discuss third quarter 2023 financial results and forward-looking financial guidance.

ACGME Releases 2022-2023 Statistics on Graduate Medical Education Programs and Resident Physicians

Retrieved on: 
Monday, October 16, 2023
Medicine, Accreditation, ACGME, Population health, Heart, Accreditation Council, Resident, Accreditation Council for Graduate Medical Education, Liaison Committee on Medical Education, Graduate medical education, Completion, Education, MACP, Mission, GME, ...Continued, Commission on English Language Program Accreditation, Physician, International, Nursing, MD

This comprehensive resource providing the graduate medical education (GME) community with the latest GME data covers the period from July 1, 2022, to June 30, 2023.

Key Points: 
  • This comprehensive resource providing the graduate medical education (GME) community with the latest GME data covers the period from July 1, 2022, to June 30, 2023.
  • During 2022-2023, there were 13,066 accredited programs, of which 5,112 were specialty programs and 6,576 were subspecialty programs with Continued Accreditation.
  • The ACGME's Data Resource Book is a comprehensive reference for those involved in graduate medical education.
  • The ACGME's Mission is to improve health care and population health by assessing and enhancing the quality of resident and fellow physicians' education through advancements in accreditation and education.

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

Retrieved on: 
Friday, September 29, 2023
Documentation, Agreement, Letter, Plan, CVR, Failure, Completeness, Tripura Merger Agreement, TD Ameritrade, Biotechnology, Stock dilution, Food and Drug Administration, Depositary, Bangladesh Securities and Exchange Commission, Schedule, Harmony, FXS, Assistance, Letter of transmittal, Fragile X syndrome, Continue, ...Continued, Less Commonly Taught Languages, Security (finance), FDA, Acquisition, Food, Personal Information Agent, Action Replay, Pharmaceutical industry, Cryptocurrency, Holding company, Sales, Mail order, Reinsurance, Money transmitter, Jean-François Zygel

The Offer was initially scheduled to expire at 5:00 p.m. New York City time on September 26, 2023.

Key Points: 
  • The Offer was initially scheduled to expire at 5:00 p.m. New York City time on September 26, 2023.
  • On September 27, 2023, Harmony announced an extension of the Offer until 5:00 p.m., New York City time, on Tuesday, October 10, 2023, to allow for additional shares to be tendered by stockholders.
  • I am reaching out to remind you to tender your shares prior to the expiration of the Offer on October 10, 2023.
  • The Zynerba Board unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer.

Paychex, Inc. Reports First Quarter Fiscal 2024 Results:

Retrieved on: 
Wednesday, September 27, 2023
Professional Services, Technology, Insurance, Software, Human Resources, Workforce, Professional employer organization, PEO, Marketing, GAAP, Ratio, Vanguard Managed Solutions, Retirement, ...Continued, Artificial intelligence, Small business, Growth, HCM, Bank, Video game, Consultant, Security (finance)

Please refer to the "Non-GAAP Financial Measures" section on page 3 of this press release for a discussion of non-GAAP measures.

Key Points: 
  • Please refer to the "Non-GAAP Financial Measures" section on page 3 of this press release for a discussion of non-GAAP measures.
  • President and Chief Executive Officer, John Gibson commented, “We are off to a strong start for fiscal 2024 with 7% growth in total revenue and 11% for adjusted diluted earnings per share.
  • Our effective income tax rate was 23.7% for the first quarter compared to 22.9% in the prior year period.
  • Cash flow from operations was $655.8 million for the first quarter.